BioLargo's New Breed Ultra-Safe Yet Powerful Disinfectant Could Play Major Role In $16 Billion Conventional Toxic Disinfectant Market – Shares Could Soar

September 25, 2020 -- InvestorsHub NewsWire -- via BioResearchAlert -- 
  • Toxicity of conventional disinfectants greatly limits usage. A non-toxic disinfectant with unrestricted use would be far more effective and would likely experience rapid uptake in a $16 billion market that is exploding due to the COVID-19 pandemic
  • Conventional disinfectants containing chlorine, bleach, alcohol, ammonia or peroxide are toxic and for use only on surfaces and not for human contact
  • CDC claims "even low level exposure to chlorine (ingredient in bleach) can result in nose, throat, and eye irritation. At higher levels, breathing chlorine gas may result in changes in breathing rate and coughing, and damage to the lungs"
  • CDC reports calls to poison centers due to disinfectant exposures increased by 20% in Q1 2020
  • BioLargo (BLGO: OTCQB) Clyraguard and CupriDyne disinfectant technology is game-changing because it is proven ULTRA-SAFE, non-toxic, colorless, and non-staining
  • BioLargo's medical subsidiary is launching Clyraguard, a hospital grade personal protection spray for PPE, including facemasks, that is safe on skin. Clyraguard is recently FDA registered and proven safe and effective at 99.999%
  • Clyraguard helps solve face mask shortage by allowing face masks to be reused safely and effectively
  • The Galveston National Laboratory at the University of Texas Medical Branch, tested and found BioLargo's CupriDyne for environmental use and ClyraGuard for medical use effective for complete inactivation of SARS-CoV-2
  • The unprecedented safety of CupriDyne and Clyraguard combined with the broad spectrum of pathogens they have been proven to kill strongly suggest that this is the biggest breakthrough in history in the $16 billion disinfectant market
  • BioResearchAlert finds BioLargo shares highly undervalued and positioned for dramatic growth for both the short and the long-term. Share price is $.16 with market cap of only $35 million

The COVID-19 pandemic has caused demand for disinfection products to skyrocket to the point where suppliers are struggling to meet demand. The problem is compounded by the fact that bleach disinfectants are the most commonly used products in spite of CDC warnings that even "low level exposure to chlorine (which is the active ingredient in bleach) can result in nose, throat, and eye irritation. At higher levels, breathing chlorine gas may result in changes in breathing rate and coughing, and damage to the lungs. Additional symptoms of exposure to chlorine can be severe. Workers may be harmed from exposure to chlorine. The level of exposure depends upon the dose, duration, and work being done." These potential hazards greatly limit and reduce the amount of conventional disinfectants that can be used to combat COVID-19.

The CDC reports calls to poison centers due to cleaning and disinfectant exposures increased by 20% in early 2020. In line with toxicity claims, the CDC reports that during January - March 2020, poison centers received 45,550 exposure calls related to cleaners (28,158) and disinfectants (17,392), representing overall increases of 20.4% and 16.4% from January - March 2019 (37,822).

New Breed Disinfectant Is Proven Safe and Proven to Completely Inactivate SARS- CoV-2

BioLargo, Inc. (BLGO: OTCQB) has developed, patented, and proven that Clyraguard for medical use and CupriDyne for environmental use both completely inactivate SARS-CoV-2 as well as a broad spectrum of problematic pathogens, and has demonstrated unrivaled safety to humans in rigorous FDA trials.

One of the first applications for Clyraguard is an FDA registered Personal Protection Spray to inactivate SARS-CoV-2 from face masks and PPE. The beginning inventory of 25,000 bottles of Clyraguard was sold out in one day and management believes sales could grow dramatically. Production has been ramped up to be able to handle orders up to 1,000,000 bottles per month and major distribution channels have been opened supported by a credit line to handle mushrooming orders. With record demand for a safe disinfectant, and a safe and convenient solution to reuse face masks that are in short supply, sales have the potential to grow to very large numbers in a relatively short time. Q3 2020 sales are expected to be the first indication of soaring sales.

This short interview of Dr. Steven DeAngeles shows how Clyraguard can protect millions of people wearing a mask. Clyraguard is so safe that it can be sprayed on the mask while the mask is still on the users face.

Clyraguard technology has been recently approved by the FDA for wound care. The company announced that further studies are planned to demonstrate better patient outcomes and substantial cost savings. If these studies confirm better patient outcomes and substantial cost savings over the current standard of care which is Betadine or Povodone (a form of iodine) Clyraguard products could become the standard of care to prevent wound infections in all surgical procedures globally. Potential sales could achieve billions of dollars.

Cupridyne for environmental spraying and coating was recently tested at one the world's leading Infectious Disease Labs, UTMB – Galveston National Lab, and found to completely inactivate SARS-CoV-2 in 10 minutes.

BioLargo announced they are pursuing an EPA registration for CupriDyne which, if approved, could result in massive sales since there is no other product that can boast the unrivaled safety and efficacy of CupriDyne technology.

Leading Suppliers of Disinfectants

Proctor & Gamble PG: NYSE

3 M Company MMM: NYSE

Kimberly Clark KMB: NYSE

Ecolab ECL: NYSE

Clorox Company CLX: NYSE


Key Investor Takeaway

What would it mean to the $16 billion disinfection industry if there was a powerful disinfectant that would inactivate viruses like SARS-CoV-2, and destroy harmful bacteria, fungi and biofilm, but that was truly safe and gentle and did not harm healthy tissue such as skin, nose, throat, eyes, lungs or mucous membranes? If it was competitively priced, marketed effectively, and well capitalized, it seems that in time, it could have the potential to become a new standard for disinfection.

BioLargo is also commercializing highly disruptive technology for the very large markets of Water Treatment and Air Quality / Odor Control. The waste handling and water treatment industries are in the early stages of adopting CupriDyne to solve multi-billion-dollar problems which all point to blockbuster sales. Commercial pilots have already begun in the poultry industry for a new generation of water treatment using BioLargo's breakthrough AOS system. Further commercial pilots are expected to launch in weeks to solve massive water treatment problems associated with stormwater, water treatment, and PFAS removal.

In conclusion, BioLargo has spent over a decade becoming what appears to be an overnight success. Well positioned to enjoy rapid uptake in multiple giant markets of medical/health, water treatment, air quality, and engineering, BioLargo represents a well-timed investment opportunity to participate in urgently needed solutions for environmental and health issues. BioLargo shares are trading at $.16 with a very small market cap of about $35 million. Share price is close to historic lows just as the company is taking off with very meaningful products and services.

BioResearchAlert believes BioLargo is a rare find and that investors should consider purchasing shares for long-term hold that have the potential to become a star performer in any portfolio and in a relatively short time frame since almost every product is disruptive and in early stages of commercialization.

 SOURCE: BioResearchAlert